Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | F10 | P00742 | 1/20 | 0.49 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19494267 | 0.89 | PKM (0.50) | PKMF10PDE10AKDM4EKMT2A | |
| SCHEMBL16188990 | 0.87 | GAA (0.51) | PKMF10PDE10AALDH1A1KMT2A | |
| SCHEMBL16188974 | 0.81 | KMT2A (0.64) | PKMF10PDE10AKDM4EKMT2A | |
| SCHEMBL12264335 | 0.80 | GAA (0.62) | F10PDE10AKDM4EALDH1A1CYP1A2 | |
| SCHEMBL16188967 | 0.80 | IDO1 (0.60) | PKMF10KMT2AIDO1CBFB | |
| SCHEMBL7332580 | 0.77 | F10 (0.53) | PKMF10PDE10AKDM4EALDH1A1 | |
| SCHEMBL28503804 | 0.77 | KDM4E (0.45) | F10PDE10AKDM4EALDH1A1CYP1A2 | |
| SCHEMBL22584708 | 0.77 | CACNA1H (0.62) | PKMF10PDE10AKDM4EALDH1A1 | |
| SCHEMBL16810842 | 0.77 | TDP1 (0.54) | F10PDE10AKDM4EALDH1A1CYP1A2 | |
| SCHEMBL1941487 | 0.77 | PDE10A (0.49) | F10PDE10AKDM4EALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9708307-B2 | Heterocyclic acetamide compound | ASTELLAS PHARMA INC. (JP) | 2017-07-18 | — | — | US | disclosed |
| US-20150045402-A1 | HETEROCYCLIC ACETAMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2015-02-12 | — | — | US | disclosed |
| US-8937087-B2 | Heterocyclic acetamide compound | ASTELLAS PHARMA INC. (JP) | 2015-01-20 | — | — | US | disclosed |
| US-20140315963-A1 | HETEROCYCLIC ACETAMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2014-10-23 | — | — | US | disclosed |
| EP-0869787-A4 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 1999-03-24 | — | — | EP | disclosed |
| EP-0869787-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-10-14 | — | — | EP | disclosed |
| WO-1997024119-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315963-A1 | HETEROCYCLIC ACETAMIDE COMPOUND | DRD1, DRD2, OPRD1 | PKM 2819/4885F10 4166/4885PDE10A 430/4885 |
| US-20150045402-A1 | HETEROCYCLIC ACETAMIDE COMPOUND | DRD2, DRD1, OPRD1 | PKM 2958/4885F10 4265/4885PDE10A 515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.